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ABSTRACT

Purpose:
In order to identify pretherapeutic predictive biomarkers in tumor biopsies of patients with locally advanced esophageal adenocarcinomas treated with neoadjuvant chemotherapy (CTX) we used an explorative proteomic approach to correlate pretherapeutic protein expression profiles with tumor response to neodadjuvant CTX.
Experimental design:
34 patients with locally advanced esophageal adenocarcinomas who received neoadjuvant platin/5FU-based CTX before surgical resection were enrolled in this 
Results:
Proteomic analysis revealed 4 cellular stress response associated proteins (HSP27, HSP60, GRP94, GRP78), and a number of cytoskeletal proteins, whose pretherapeutic abundance was significantly different (p<0.001) between responders and nonresponders. Immunohistochemistry and gene expression analysis confirmed these data demonstrating a significant association between low HSP27 expression and nonresponse to neoadjuvant CTX (p=0.049 and p=0.032 respectively).
Conclusions:
Albeit preliminary, our encouraging data suggest that protein expression profiling may distinguish cancers with different response to CTX. Our results suggest that response to CTX may be related to different activation of stress response and inflammatory biology in general. Moreover, the potential of heat shock proteins and glucose regulated proteins as biomarkers of CTX response warrants further validation.
INTRODUCTION
The incidence of adenocarcinomas of the esophagus has risen faster than any other malignancy worldwide (1, 2) . Most patients have locally advanced or metastatic disease and their prognosis is poor with a 5-year survival rate of less than 20%. The most common therapeutic approach for locally advanced esophageal adenocarcinomas is a multimodal treatment with preoperative Cisplatinum/5-FU based chemo-or radiochemotherapy followed by resection(3) . Recent randomized Phase III studies have shown a survival benefit for patients with perioperative chemotherapy compared to surgery alone for these tumors (4, 5) . Moreover, it is now generally accepted, that patients with upper gastrointestinal tumors, who respond to neoadjuvant chemotherapy have a significant improved survival compared to patients, who do not respond to induction therapy (6) . However, only 30-50 percent of the patients respond to induction therapy. Therefore the pretherapeutical identification of nonresponding patients to avoid inefficient therapy, toxic side effects and cost would be of utmost interest.
Many studies in the very recent past have been directed towards understanding the mechanism of chemotherapy response and resistance, with the ultimate goal of identifying molecular markers that allow the prediction of CTX response. For esophageal adenocarcinoma several of these studies have concentrated on expression analysis of CTX-associated genes (7, 8) of biomarkers p53 and p21 with known prognostic impact (9) and some have performed genome wide screening and gene expression profiling to identify expression signatures with potential predictive value (10) .
Proteomic analysis has emerged as a valuable tool in scientific medicine (11) (12) (13) albeit with considerable quantitative and statistical challenges (14) . As chemoresistance of tumors is a complex and multifactorial event, we performed differential quantitative protein expression analysis in an explorative setting by using the recently developed and established radioactive ProteoTope clinical proteomics platform (15) (16) (17) . In the present study we compared protein expression patterns in pretherapeutic biopsies of patients with locally advanced esophageal adenocarcinomas who showed a response to preoperative CTX with those of patients who did not respond. On the base of quantitative differential data, selected protein biomarker candidates were validated by using immunohistochemistry.
Furthermore, gene expression of those markers was analysed by using quantitative real time RT-PCR. 
MATERIALS AND METHODS
Patients and tissue specimens
Histopathologic evaluation of tumor regression
To assess histopathologic tumor regression in response to chemotherapy, the 10-50% residual tumor / tumor bed (4 patients), and tumor regression score 3: more than 50% residual tumor / tumorbed (19 patients). One patient did not undergo surgical resection due to progressive disease during CTX.
Response evaluation
Response to CTX was defined as either (a) metabolic response assessed by PET evaluation, according to Lordick et al. (18) or (b) histopathologic tumor regression (score 1). Nonreponse to CTX was defined as neither metabolic response nor histopathologic regression.
Follow-up
Overall survival was calculated from the first day of study inclusion. Event-free survival was calculated up to the time of death or relapse, whichever occurred first In patients with curative (R 0 ) resection, survival was calculated from resection to death.
No patient was lost to follow-up. Two patients showed immediate postoperative complications and were excluded from survival analysis due to an event-free survival <1 month.
Two-dimensional differential proteomic analysis
ProteoTope analysis was performed on freshly frozen, pretherapeutic biopsies of ca.
2 mm diameter. After verification of sufficient cancer tissue on a fresh frozen section and standard hematoxylin-eosin staining, protein analysis was performed on 6-10 frozen sections of 20 µm thickness in each case, and transferred into sterile tubes.
Only tumor samples with more than 60% carcinoma content compared to stroma or necrosis were included. Mean carcinoma content of responders samples was 70% (range; 60%-90%), comparable to that of nonresponders samples (mean 75%; range; 60%-90%). ProteoTope analysis was also performed on a reference sample of pooled freshly frozen surgical tissue (see below).
Protein extraction from biopsies
Sectioned frozen biopsies were sent to ProteoSys, Mainz, Germany on frozen carbon dioxide and stored at -80°C until processing. The cryo-sectioning medium constituted over 90% of each sample, and had to be removed. Each tube was filled with 1,5 mL of 80% acetone (-20°C). Slices adhering to the walls of the tube were scraped into suspension using a small spatula. Tubes were centrifuged for 1 min at 12000xg, acetone was removed and 1 mL of 50% acetone was added. The pellet containing tumor tissue was washed for 15 min by occasional vortexing. In the intervening periods the samples were kept on ice. The washing procedure was repeated five times.
After washing, the samples were centrifuged for 30 min at 30 000 RCF. Acetone was removed and the remaining 50% acetone was evaporated in a speed vac for 15 min.
Dry pellets of biopsy samples were dissolved in 35 µL of preheated (95°C) 100 mM Tris pH 7,4, 2% SDS (iodination buffer) and incubated for 5 min at 95°C. Protein determinations by the BCA method ranged from 35 µg -109 µg per biopsy (15) .
Protein extraction from reference samples
A reference sample was prepared for this study to be coelectrophoresed during 2D-PAGE with each respective test sample, and to provide comigrating reference proteins at sufficient abundance to permit protein identification by mass spectrometry.
The pooled reference sample contained proteins from nine control samples of normal Cardia and esophageal mucosa, as well as of tumor tissue of esophageal adenocarcinoma. The reference samples were dissolved with different amounts of buffer according to estimated pellet sizes. Extracts were centrifuged for 5 min at 12000 rpm and 6 µL were used to prepare a 1:10 dilution for protein determination.
This was performed using the BCA method (Bio-Rad). Protein yields measured by the BCA method ranged from 400 µg -800 µg per control sample. The reference sample for proteomics analysis was constructed by pooling together 170 µg of protein from each respective control sample, providing a reference sample of 1.5 mg protein in 203 µL iodination buffer.
Protein iodination
Proteins were iodinated by the chloramines T method and transferred to urea-based IEF buffer as recently described in detail (17) .
Radioactive 2D-gels
Protein samples in IEF-buffer (7 M urea, 1% Triton X-100, 10 % glycerol, 2 M thiourea, 4% CHAPS, 1% DTT, 0.8% IPG-buffer from Amersham Pharmacia) were loaded onto the IPG-strips pH-range 4-7. For all gels, the first dimension focussing was performed over an effective separation distance of 18 cm. Each first dimension focussing was afterwards loaded onto a second dimension SDS-PAGE-gel and radioactive proteins were imaged by ProteoTope as described. (16, 22, 23 
Data analysis
Comparisons between the two groups of responders and non-responders were performed in the following manner:.For each spot on each gel, the ratio of the abundances of the pertinent protein in the respective individual over its abundance in the reference pool was computed. The sets of these ratios originating from responders and from non-responders were formed and compared to each other using the t-test for unpaired samples, based on the null hypothesis of identical volume ratios. Spot volumes were rated to be significantly different between responders and non-responders if the t-test resulted in a p-value of less than 0.01.
Spots found to be different in responders and non-responders by ProteoTope analysis were given unique labels (selSpotID). Radioactive images of preparative gels were warped to the same target as the ProteoTope images using the Delta2d software package by Decodon (see http://www.decodon.com/). The above labels were transferred to the corresponding silver stained images of the preparative gels, and the spot coordinates of the labelled spots were exported as picklists for automatic excision and processing as described (14, 23) .
Protein Identification by Mass Spectrometry
For mass spectrometry-based identification of proteins, preparative, tracer control enrichment gels (tracer gels) were employed, where a trace of radioactively labelled protein sample, corresponding to the sample used for analytical two colour gels, is co-electrophoresed with a vast excess of non-radioactively labelled protein from the pooled reference sample (about 200 µg) to provide preparative amounts of protein for identification (22, 24) . After electrophoresis gels are silver stained according to Shevchenko et al(25) . Protein identification was based on different mass 
Validation of differential proteomic data
For validation of prospective biomarkers from the differential proteomic part, we Microdissection, RNA extraction, cDNA synthesis and RT-PCR from pooled tumor tissue from at least two biosies per case were performed as described previously (7, 26) . PCR reactions were performed in at least two replicates. Pre-developed primerprobe sets (Applied Biosystems, Foster City, CA, USA) were used for HSP27 (assay ID Hs00356629_g1), HSP60 (assay ID Hs01036747_m1), GRP78 (assay ID Hs99999174_m1) and GRP94 (assay ID Hs00427665_g1). Relative expression levels of target genes were determined by the relative standard curve method with GAPDH as normalizing housekeeping gene. Primers and probe-sequence of GAPDH are available from the authors on request.
Statistics (non-proteomic)
Validation statistical analysis was performed using non-parametric methods:
comparisons between the two groups of responders and non-responders were made using the Mann-Whitney U test. Associations in 2 × 2 tables were evaluated by X²-tests and Fisher´s exact tests. Survival analysis was performed using Kaplan-Meier estimates, log rank tests and Cox's proportional hazards regression analysis.
Correlations between Proteomic data and quantitative real time RT-PCR were made by determination of the Spearman's rank correlation coefficient (r). Association between immunohistochemical staining patterns and proteomic data were determined using Post-hoc one way ANOVA with LSD testing. All tests were 2-sided, and the significance level was set at 5%. For all validation statistical procedures SPSS 15 software (SPSS Inc, Chicago, IL) was used.
RESULTS
Patient´s descriptions are given in the material and methods section. According to the CTX-response classification described above, 20 patients were responders and 14 were nonresponders. There was no difference in tumor-grading assessed in pretherapeutic biopies between responders and nonresponders. ypT0 and ypT1
stages were more frequent seen in responders (p=0.11) as well as ypN0 stages 
Proteomics-Analysis
ProteoTope analysis was performed on fresh frozen, pretherapeutic biopsies of 20 patients. Proteins found to be differentially abundant (p<0.001) between responders and non-responders classed over the entire data set are depicted in table 2. All proteins designated as 'not identified' were subjected to at least two separate MS/MS measurements to improve the certainty of identification. The ion intensities generated by peptides from these proteins were too weak to permit suitable MS/MS identifications. A notable feature of table 2 is that there are no proteins which were identified to be unambiguously and systematically more abundant in the nonresponder biopsies with the exception of only one unidentified spot (R3_3685), which was at the low molecular weight basic region (ca. pH 6.7) of the gels. This was not due to systematically weaker signal intensities for non-responder gels, which was manually verified by inspection of total gel intensities for all samples. The protein spots from non-responders exhibited signal intensities similar to those of responders.
This situation is unusual in proteomic studies, and as such it is noteworthy and is consistent with the response to therapy putatively requiring the pretherapeutic underlying susceptibility to an increased induction of a biological stress response which we will discuss below.
Differentially expressed and identified proteins found by ProteoTope-Analysis could be subdivided into two major groups: one group includes cytoskeletal proteins, such as actin alpha1, beta and gamma1, as well as tubulin, desmin, tropomyosin and vimentin.
The second group includes the heat shock proteins HSP27, HSP60 and glucose regulated proteins GRP78 and GRP94, belonging to the molecular chaperone family.
We chose the latter for further validation due to (a) the conclusion that the difference between responders and non-responders may involve the differential activation of a stress response and (b) recent reports concerning the role of molecular chaperones in tumor resistance to chemotherapeutics (27, 28) . 
Immunohistochemistry
Gene expression Analysis (Quantitative real-time RT-PCR)
The expression of the 4 selected genes was detectable in formalin fixed, paraffin embedded biopsy samples of 31 patients.
There was no significant correlation between ProteoTope data and mRNA expression Using this definition of CTX response, significantly differentially expressed and identified proteins found by ProteoTope proteomics were cytoskeletal proteins (aktin, tubulin, desmin, tropomyosin and vimentin) and the heat shock proteins HSP27, HSP60 and glucose regulated proteins GRP78 and GRP94, which are members of the molecular group of the chaperone family.
Concerning the first mentioned group of proteins differentially expressed in responders and nonresponders, it is rather unclear why responders exhibit increased levels of certain cytoskeletal components. Since not all cytoplasmic proteins were detected as differential, it is unlikely that this difference reflects a general enlargement of cytoplasmic mass in responders. Rather, it is possible that these proteins are repressed in non-responders. One study describes an upregulation of proteins actin gamma, tropomyosin and tubulin alpha (amongst many other proteins)
in a cervix carcinoma cell line after cisplatin-treatment (31) . Another study shows an association between the expression of some tubulin isoforms and response to docetaxel (32) . However, only half of the patients investigated in our study were treated by taxanes (paclitaxel) so involvement of the microtubule system alone may not provide an explanation. Therefore, the underlying causes of this phenomenon merit further examination.
Due to very recent reports on the interaction between molecular chaperones and tumor resistance to CTX (27, 28) we decided to validate the identified proteins HSP27, HSP60, GRP78 and GRP94 using immunohistochemistry and to analyse them also at the gene expression level using quantitative real time RT-PCR.
Two members of the glucose-regulated proteins (GRPs) were identified to be differentially expressed in responders and nonresponders. GRP78, also referred to as immunoglobulin heavy chain binding protein (BiP), and GRP94, also referred to as GP96, are the best studied members of the family of glucose-regulated proteins (GRPs). GRP94 and GRP78 are constitutively located within the ER and perform normal physiological functions under moderate levels of basal expression. Because of their ability to assist in protein folding and assembly, the GRPs are referred to as molecular chaperones (33) . Synthesis of GRPs is enhanced under pathological conditions, such as glucose-starvation, acidosis, hypoxia or hypothermia. In tumor cells the induction of GRP94 or GRP78 may also represent a defence mechanism for the survival of cancer cells exposed to these stress conditions or to the immunological response of the host.
In human cancers, like breast cancer (34, 35) , prostate cancer (36), colorectal cancer or lung cancer, there has been the general observation that higher GRP levels correlate with higher pathological grade and aggressive behaviour. However, in addition to intratumoral or intracellular conditions, the regulation of GRP expression in tumor cells may be dependent upon exposure to various extratumoral stress factors such as the potency of the immunological answer of the host, hypoxia or cytotoxic treatment (37) .
We recently have demonstrated an association of GRP78 and GRP94 mRNA and protein expression with tumor stage and behaviour in esophageal adenocarcinomas:
Increased expression of GRP78 was mainly observed in early tumor stages, but also in a few patients with advanced tumor stages (38) . Tumors of this latter subset of patients with high GRP tumor levels may be exposed to special cellular stress conditions that may lead to increased chemosensitivity. Others have also reported on the relationship between induction of GRPs and tumor resistance against CTX treatment. In contrast to our findings, high GRP78 expression levels were associated with tumor resistance to CTX in breast (39) and prostate (40) 
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TABLES
Patient´s characteristics: PLF=Cisplatin (oxaliplatin)/ folinic acid/5-fluorouracil T=paclitaxel. G=Tumor grading. TRG=tumor regression grade. PET=PET response (R/NR). EFS=event free survival.
*patients were excluded from survival analysis due to an event-free survival <1 month (immediate postoperative complications) Table 2 .
Proteo-Tope-Analysis: protein spot quantification in pretherapeutic biopsies of MALDI-TOF PMF scores are from MASCOT.
PMF=potential of mean force. n.i.=not identified. Table 3 .
Immunohistochemistry: staining patterns of HSP27, HSP60, GRP78 and GRP94 in formalin fixed, paraffin embedded biopsies of responders and nonresponders to neoadjuvant CTX. *p=0.049 for negative/weak HSP27-expression vs. moderate and strong. RT-PCR Analysis: Median gene expression levels with 95% confidential intervals (CI) (gene/GAPDH) of HSP27, HSP60, GRP78 and GRP94 in formalin fixed, paraffin embedded biopsies of responders and nonresponders to neoadjuvant CTX. 
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